LA JOLLA – Torrey Pines biotech innovator Capricor Therapeutics (Nasdaq: CAPR) signed a massive new deal with Japanese biopharma leader Nippon Shinyaku (TYO: 4516) for the European commercialization and distribution of Capricor’s leading drug – deramiocel – for the treatment of Duchenne muscular dystrophy (DMD), a debilitating genetic disorder that causes progressive muscle degeneration and […]
↧